Table 1. Baseline characteristics.
| Placebo | Exenatide 5 μg | Exenatide 10 μg | P† | |
|---|---|---|---|---|
| n = 35 | n = 72 | n = 72 | ||
| Sex (male), % | 24 (68.6) | 49 (68.1) | 49 (68.1) | 0.998 |
| Age (years) | 56.3 ± 11.4 | 58.5 ± 9.3 | 59.4 ± 9.8 | 0.321 |
| Weight (kg) | 70.3 ± 13.3 | 67.0 ± 11.5 | 69.1 ± 11.2 | 0.348 |
| Body mass index (kg/m2) | 25.8 ± 4.2 | 25.0 ± 4.1 | 25.8 ± 3.9 | 0.391 |
| Duration of type 2 diabetes (years) | 12.4 ± 6.5 | 12.2 ± 6.3 | 11.6 ± 7.0 | 0.764 |
| HbA1c (%) | 8.1 ± 0.9 | 8.3 ± 0.8 | 8.2 ± 1.0 | 0.679 |
| FPG (mg/dL) | 160 ± 31.4 | 164 ± 41.5 | 164 ± 39.0 | 0.818 |
| Total cholesterol (mg/dL) | 201 ± 25.7 | 204 ± 35.7 | 202 ± 30.8 | 0.880 |
| HDL cholesterol (mg/dL) | 56 ± 12.5 | 57 ± 14.9 | 55 ± 10.6 | 0.556 |
| LDL cholesterol (mg/dL) | 123 ± 24.0 | 124 ± 28.3 | 125 ± 27.1 | 0.917 |
| Triglycerides (mg/dL) | 126 ± 79.2 | 133 ± 95.1 | 131 ± 69.8 | 0.914 |
| Oral anti‐diabetic agents at informed consent | ||||
| SU alone | 3 (8.6) | 4 (5.6) | 8 (11.1) | |
| SU + α‐GI | 3 (8.6) | 1 (1.4) | 4 (5.6) | |
| SU + BG | 14 (40.0) | 33 (45.8) | 27 (37.5) | |
| SU + BG + α‐GI | 9 (25.7) | 22 (30.6) | 13 (18.1) | |
| SU + BG + meglitinide derivative | 0 (0.0) | 0 (0.0) | 1 (1.4) | |
| SU + TZD | 4 (11.4) | 6 (8.3) | 12 (16.7) | |
| SU + TZD + α‐GI | 2 (5.7) | 6 (8.3) | 7 (9.7) | |
Data are n (%) or means ± SD for the full analysis set. α‐GI, α‐glucosidase inhibitors; BG, biguanide; FPG, fasting blood glucose; SU, sulfonylurea; TZD, thiazolidine derivative. †P for comparison among the treatment groups.